Silo Pharma (SILO): CEO bought ~$1K
Eric Weisblum, CEO at Silo Pharma, bought ~$1K of Silo Pharma shares.
- ~$1K
- Approx. value · 2,500 sh @ $0.41
- 214K
- Holds after · shares reported
- Traded
- Dec 15, 2025
- Filed
- Dec 16, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 24, 2025Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“At the Annual Meeting (as defined below) on October 24, 2025, the shareholders of Silo Pharma, Inc. (the “Company”) approved an amendment to the Silo Pharma Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan (the “Plan Amendment’) to increase the number of shares of common stock reserved for issuance thereunder to 1,400,000 shares from 470,000 shares.”
- Nov 18, 2025InsiderCEO purchased ~$3K of SILO shares in the open market
- Nov 19, 2025InsiderCEO purchased ~$1.8K of SILO shares in the open market
- Nov 20, 2025InsiderCEO purchased ~$370 of SILO shares in the open market
- Nov 21, 2025InsiderCEO purchased ~$365 of SILO shares in the open market
- Dec 15, 2025 · this disclosureInsider · 9 days before an 8-KCEO purchased ~$1K of SILO shares in the open market
What came next
- Dec 15, 2025Insider · 9 days before an 8-KCEO purchased ~$1.1K of SILO shares in the open market
- Dec 24, 2025Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously disclosed in a Current Report on Form 8-K filed by Silo Pharma, Inc. (the “Company”) on June 27, 2025, the Company received a notification (the “Notification Letter”) from The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.”
- Feb 20, 2026Company filing · Form 8-K · Unregistered shares, Other newsSold new shares without registering them, and reported other company news
- Mar 30, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Silo Pharma
For Silo Pharma, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SILO page.
Other recent filings by Eric Weisblum, Chief Executive Officer
- SEC Form 4 at Silo Pharma (SILO)Dec 16, 2025
- SEC Form 4 at Silo Pharma (SILO)Nov 21, 2025
- SEC Form 4 at Silo Pharma (SILO)Nov 21, 2025
- SEC Form 4 at Silo Pharma (SILO)Nov 20, 2025
- SEC Form 4 at Silo Pharma (SILO)Nov 20, 2025
The full history of Eric Weisblum, Chief Executive Officer is on the profile page.
How this filing works
Explore the data
Common questions
Which Silo Pharma (SILO) insider traded, and how much?
Eric Weisblum, CEO at Silo Pharma, bought ~$1K of Silo Pharma shares. 2,500 shares at $0.41, open market.
When did it happen, and when was it made public?
Traded: Dec 15, 2025. Filed: Dec 16, 2025. That is 1 day between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Silo Pharma recently?
For Silo Pharma, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the SILO page.
Does this mean SILO stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Silo Pharma
- SEC Schedule 13GNov 16, 2026
- SEC Form 4Dec 16, 2025
- SEC Form 4Nov 21, 2025
- SEC Form 4Nov 21, 2025
- SEC Form 4Nov 20, 2025
- SEC Form 4Nov 20, 2025
Everything OQRO holds on this company is on its SILO page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
